Saturday, May 25, 2019

The U.S. Food and Drug Administration on Friday approved Incyte Corp's treatment for acute Graft versus Host disease (GvHD), an inflammatory response by the immune system after a bone marrow transplant.


from Reuters: Health News https://reut.rs/2YFQp4e

Related Posts:

  • LATEST HEALTH NEWSBayer shares continued to fall on Tuesday after a California jury on Monday awarded more than $2 billion in damages to a couple who alleged that the company's glyphosate-based weed killer Roundup caused their cancers. fr… Read More
  • LATEST HEALTH NEWS(Reuters Health) - Informal care for older relatives continues to affect the labor market, and the effects remain gendered, according to a new study in Canada. from Reuters: Health News https://reut.rs/2JkmhYn … Read More
  • LATEST HEALTH NEWSA California jury on Monday awarded more than $2 billion to a couple who claimed Bayer AG's glyphosate-based Roundup weed killer caused their cancer, in the largest U.S. jury verdict to date against the company in litigation … Read More
  • LATEST HEALTH NEWS(Reuters Health) - Severely obese women who opt for weight-loss surgery may be cutting their risk of breast cancer along with their extra pounds, a large U.S. study suggests. from Reuters: Health News https://reut.rs/30j… Read More
  • LATEST HEALTH NEWSBayer shares fell by as much as 5 percent on Tuesday after a California couple were awarded more than $2 billion in the largest U.S. jury penalty over allegations its Roundup weed killer causes cancer. from Reuters: Heal… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner